SkyDance Vascular to Show OspreyIV at Vizient Exchange

SkyDance Vascular will exhibit its Osprey Midline Closed IV Catheter System at Vizient’s Innovative Technology Exchange on Sept. 24 in Las Vegas. The selection puts the company’s through-the-needle catheter platform in front of hospital supply chain and clinical leaders as it seeks broader adoption in vascular access.

Why it matters: - Vizient’s Innovative Technology Exchange gives SkyDance Vascular access to hospital supply chain and clinical leaders who influence purchasing and adoption decisions. - The OspreyIV platform is built to address catheter contamination, vessel trauma, needlestick injury and catheter failure in one system. - The company is positioning the product as a way to help clinicians extend dwell times, improve therapy completion and support a better patient experience.

What happened: - SkyDance Vascular was selected to exhibit its Osprey Midline Closed IV Catheter System at the Vizient Innovative Technology Exchange. - Vizient will hold the Exchange on Sept. 24 in Las Vegas. - The annual event brings selected suppliers in front of Vizient hospital clients and subject matter experts from supply councils. - Each product or service at the Exchange is meant to show clinical, safety or business-model improvements.

The details: - The Osprey Midline Closed IV Catheter System is described as the only available vascular access device platform that deploys a vascular catheter through a needle. - The system combines Skin Avoidance Technology, a Bevel-Only Insertion technique, Passive Needle Retraction and Contoured Directional Flow. - Those features are designed to protect the catheter during insertion, reduce insertion-related contamination, support successful placement and preserve the vessel. - The platform is also designed to provide protection against needlestick injury. - SkyDance Vascular says the product maintains an intuitive clinical workflow while addressing risks tied to contamination, vessel trauma and catheter failure. - Bill Bold, chief executive officer of SkyDance Vascular, said the selection gives the company a chance to present Osprey Midline directly to leaders who understand peripheral vascular access challenges. - Kelly Flaharty, associate vice president of contract operations at Vizient, said the Exchange offers providers a way to engage with products that may influence clinical care and organizational business models. - Vizient’s Innovative Technology Program includes product review of supplier-submitted technologies by provider-led councils. - Vizient has reviewed more than 1,700 product submissions through the program since 2003.

Between the lines: - The selection is a commercialization milestone as much as a clinical one, because it places the platform in front of decision-makers who can shape rollout across hospital systems. - SkyDance Vascular is trying to frame through-the-needle deployment as a simpler answer to multiple vascular access pain points rather than a single-feature improvement. - The company’s pitch centers on safety, preservation of the vessel and workflow efficiency, which are common buying criteria in hospital access products.

What's next: - SkyDance Vascular will demonstrate Osprey Midline at the Sept. 24 Exchange. - The company will use the event to show how the system protects the catheter, preserves the vessel and supports patient outcomes. - Broader adoption will depend on how Vizient-affiliated providers evaluate the product during and after the Exchange.

The bottom line: - SkyDance Vascular is taking OspreyIV to a high-visibility buying forum at a time when hospitals are looking for vascular access products that improve safety and reliability.